<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Poirel L</submitter><funding>Swiss National Science Foundation</funding><funding>University of Fribourg</funding><pubmed_abstract>CTX-M-type extended-spectrum ß-lactamases (ESBL) are widespread among Enterobacterales worldwide. The most common variant is CTX-M-15 hydrolyzing ceftazidime at high rate, but sparing carbapenems. We identified here CTX-M-33, a point mutant derivative of CTX-M-15 (Asp to Ser substitution at Ambler position 109), exhibiting a low carbapenemase activity. ß-Lactamase CTX-M-33 was identified in a Klebsiella pneumoniae isolate belonging to ST405, lacking the outer membrane protein OmpK36, that was resistant to broad-spectrum cephalosporins and ß-lactam/ß-lactamase inhibitor combinations, and displayed a decreased susceptibility to carbapenems. Comparative hydrolytic activity assays showed that CTX-M-33 hydrolyzed ceftazidime at a lower level than CTX-M-15, but significantly hydrolyzed meropenem. In addition, CTX-M-33 showed higher Mutant Prevention Concentration values and wider mutant selection window in presence of meropenem, in accordance with its observed hydrolytic properties. We identified here the very first CTX-M enzyme possessing a weak carbapenemase activity, that may correspond to an emerging phenomenon when considering its possibility to evolve from the widespread ESBL CTX-M-15.</pubmed_abstract><journal>Antimicrobial agents and chemotherapy</journal><pagination>AAC.01515-19</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6879240</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>CTX-M-33, a CTX-M-15 derivative conferring reduced susceptibility to carbapenems.</pubmed_title><pmcid>PMC6879240</pmcid><funding_grant_id>177381</funding_grant_id><funding_grant_id>407240</funding_grant_id><funding_grant_id>163432</funding_grant_id><pubmed_authors>Aires-de-Sousa M</pubmed_authors><pubmed_authors>Ortiz de la Rosa JM</pubmed_authors><pubmed_authors>Nordmann P</pubmed_authors><pubmed_authors>Richard A</pubmed_authors><pubmed_authors>Poirel L</pubmed_authors></additional><is_claimable>false</is_claimable><name>CTX-M-33, a CTX-M-15 derivative conferring reduced susceptibility to carbapenems.</name><description>CTX-M-type extended-spectrum ß-lactamases (ESBL) are widespread among Enterobacterales worldwide. The most common variant is CTX-M-15 hydrolyzing ceftazidime at high rate, but sparing carbapenems. We identified here CTX-M-33, a point mutant derivative of CTX-M-15 (Asp to Ser substitution at Ambler position 109), exhibiting a low carbapenemase activity. ß-Lactamase CTX-M-33 was identified in a Klebsiella pneumoniae isolate belonging to ST405, lacking the outer membrane protein OmpK36, that was resistant to broad-spectrum cephalosporins and ß-lactam/ß-lactamase inhibitor combinations, and displayed a decreased susceptibility to carbapenems. Comparative hydrolytic activity assays showed that CTX-M-33 hydrolyzed ceftazidime at a lower level than CTX-M-15, but significantly hydrolyzed meropenem. In addition, CTX-M-33 showed higher Mutant Prevention Concentration values and wider mutant selection window in presence of meropenem, in accordance with its observed hydrolytic properties. We identified here the very first CTX-M enzyme possessing a weak carbapenemase activity, that may correspond to an emerging phenomenon when considering its possibility to evolve from the widespread ESBL CTX-M-15.</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Sep</publication><modification>2024-02-14T13:50:00.76Z</modification><creation>2020-05-24T07:08:30Z</creation></dates><accession>S-EPMC6879240</accession><cross_references><pubmed>31527021</pubmed><doi>10.1128/AAC.01515-19</doi><doi>10.1128/aac.01515-19</doi></cross_references></HashMap>